Pharmacy Board bans sale of unregistered Indian Pharmacopeia products

The Pharmacy and Poisons Board has flagged unregistered pharmaceutical products from Indian Pharmacopeia.

In a statement, the board directed all industry stakeholders to immediately halt the trading, importing or handling of these and other unregistered products.

PPB CEO Felix Siyoi expressed concern over the increasing influx of such products into the Kenyan market and warned that failure to comply with the directive would result in severe regulatory actions.

These could include seizure of the products, revocation of licenses, and prosecution as stipulated under the law.

“The Board’s attention has been drawn to an increasing influx of unregistered pharmaceutical products in the Kenyan market, particularly those referencing the Indian Pharmacopeia (IP). Note that any pharmaceutical product that is not duly registered by the Pharmacy and Poisons Board is strictly prohibited for importation, distribution, sale, or handling in Kenya” he said.

“The Indian Pharmacopeia is not within the purview of drug registration requirements in the country, and as such products citing this standard are not compliant with Kenyan regulations” he stressed.

He stated that the regulator will continue fulfilling its mandate to ensure access to quality, safe, effective, and affordable health products and technologies.

“The Pharmacy and Poisons Board will continue to monitor the market and take necessary enforcement actions to ensure compliance with the applicable regulatory framework” he stated.